Coronavirus Treatment : Prospective Vaccines / Drugs

The newly wide-spread SARS-CoV-2 is prevailing across the globe. The outbreak caused by the coronavirus has upheaved lives and led to an impending economy crash. Revolting against this pandemic are our front end health line workers. Although till date no vaccine or drug has been developed which prevents the Covid-19 disease but several patients who were infected by the Coronavirus have been cured. This has fueled the healthcare officials and researchers in the major pharmaceutical and bio-medical industries to comb through the existing trove of medicines and find a vaccine for as the cure against the Coronavirus.

 

 

Favilavir (Favipiravir)

This anti-viral drug has been approved by The National Medical Products Administration of China as a treatment for Coronavirus. This was used for the treatment of Influenza. During the human trials it showed efficiency in the treatment of coronavirus.

 

Fusogenix DNA Vaccine

The Fusogenix drug delivery platform is used against the coronavirus infection. The Fusogenix drug delivery platform is a proteo-lipid vehicle and this delivers its genetic payload directly inside the organism cells. The DNA vaccine is being prepared by the Entos Pharmaceuticals. Protein epitopes are being derived from the SARS-Cov-2 virus. The company is trying to develop an optimized payload which encloses multiple protein epitopes to instigate an immune response in the Covid-19 patient.

 

ChAdOx1 nCoV-19

The Jenner institute is developing an Adeno virus vaccine vector. The weakened version of common cold virus is genetically altered by adding Spike Glycoproteins which are found o the surface of the coronavirus. The change has been made in the ChAdOx1 virus to make it compatible for the human host as it primarily infects the chimpanzees. The Astra Zeneca’s vaccine was found at the University of Oxford.

 

Gimisilumab

Covid -19 in its last stages causes an inflammation of myeloid cells and thus infiltrates and damages the tissues. This is also known as the Cytokine Storm. The Gimisilumab is a human monoclonal antibody which inhibits the granulocyte-macrophage colony stimulating factor (GM-CSF) as this leads to high levels of pro-inflammatory cytokine in serum of the person infected by the Coronavirus.

 

The biopharmaceutical company Roviant Sciences is working on clinical development of Gimisilumab for treating the Acute Respiratory Distress Syndrome which is associated with the SARS-Cov-2 virus infection.

 

TZLS-501

This is a Human Monoclonal Antibody which targets the Interleukin-6 receptor (IL-6R) and reduces the elevated level of IL-6 in the body. Tiziana Life Sciences is developing this drug which binds to the Interleukin as it is responsible for chronic inflammation of lungs  (ARDS).

 

BPI-002

A New York based Bio-pharmaceutical Company Beyond spring Inc. has recently filed a provisional U.S patent for its BPI-002 drug which is said to be effective against the viral infections including Covid-19. The drug can be orally administered. BPI-002 when combined attenuated coronavirus vaccine elicits an Immune response by activating CD4 and CD8 receptors, thus stimulating the helper T cells and the cytotoxic cells.

 

 INO-4800 DNA Vaccine

Inovio Biotechnological Company has collaborated with the Germany based Richter-Helm BioLoics for the advancement of the INO-4800 DNA vaccine against the SARS-Cov-2 virus which causes Covid-19. Coalition for Epidemic Preparedness Innovations (CEPI) is providing the funds for this agreement. Recombinant subunit vaccine

Clover Biopharmaceuticals and Dynavax Technologies Corporation have started a research collaboration for developing a trimeric S protein based vaccine (COVID-19 S-Trimer) by utilizing Clover’s patented Trimer-Tag techonology and Dynavax’s CpG 1018 adjuvant.

 

BXT-125

BIXT Biotechnological Company has invited collaborations for the development of its BX-25 drug for treating Acute Respiratory Distress Syndrome (ARDS) in the Covid-19 patients. In the late stages of the infection the patient’s vital organs are filled with fluid as the blood lacks diffused oxygen. BIOXYTRAN INC’s drug is 5000 times smaller than the blood cells and thus capable of transporting oxygen throughout the body. The drug continuously circulates with the half-life of 9 hours until it is processed by the liver.

 

Remdesivir (GS-5734) is an anti-viral drug created by the American Biopharmaceutical company Gilead Sciences Inc. This prodrug of the parent Adenosine Analog is a broad spectrum small molecule. Both Remdesivir and the adenosine analog (GS-441524) when metabolized in the body turn into active Nucleoside Triphosphate (NTP) and have showed efficacy against the coronavirus.

 

Galidesivir

Galidesivir (BCX4430) is an Adenosine analog broad spectrum anti-viral drug being developed by BioCryst Pharmaceuticals. It is a Nucleoside RNA polymerase which inhibits the process of replication in the virus.

 

BNT162 RNA Vaccine

Biopharmaceutical New Technologies (BioNTech) and Pfizer Inc. have developed BNT162 vaccine. This is a modified nucleoside (mRNA) vaccine against covid-19 which is capable of generating an antigen-antibody immune response. 

 

The industry giants are also trying combination of various existing drugs as potential therapies. Many pharmaceutical companies like Johnson & Johnson, Roche, AstraZenca, Sanofi and Moderna are sprinting for finding the cure.

Services Offered

Explore Our Core Services

Empowering innovation through comprehensive IP research, analytics, and legal intelligence solutions.

Patent Landscape Analysis

Comprehensive landscape studies revealing R&D trends, white spaces, and competitive intelligence across technology domains.

Learn More

Freedom to Operate (FTO)

Assess infringement risks and ensure product clearance through detailed patent and legal status evaluation.

Learn More

Invalidity / Opposition Search

Identify prior art to challenge patent validity or strengthen litigation and post-grant opposition strategies.

Learn More

Patent Monitoring

Stay updated on competitor filings, industry movements, and evolving technology trends with continuous IP tracking.

Learn More

Patent Drafting & Filing

End-to-end patent application drafting and filing services that meet jurisdictional requirements and business goals.

Learn More

Patent Valuation

Accurately assess the commercial worth of patents and portfolios for M&A, licensing, or strategic decision-making.

Learn More

Technology Scouting

Identify emerging technologies, potential collaborators, and innovation opportunities aligned with your R&D roadmap.

Learn More

Competitive Intelligence

Analyze competitors’ IP strategies and technology portfolios to guide informed business and R&D investments.

Learn More

Trademark Search & Registration

Protect your brand identity through global trademark search, registration, and monitoring services.

Learn More

Design Registration

Safeguard the visual uniqueness of your product with professional design search, drafting, and registration services.

Learn More

Licensing & Commercialization Support

Maximize revenue from IP assets through licensing strategy, deal support, and commercialization insights.

Learn More

IP Due Diligence

Detailed IP audits and risk analysis to support investment, merger, and acquisition decisions.

Learn More

Discover More